Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.
将 6-不饱和 n-6
脂肪酸,特别是
丙三酸(G
LA)、二氢
丙三酸(DG
LA)或
花生四烯酸(
AA),连同可降低细胞内
山梨醇水平的药学上可接受的物质,特别是醛糖还原酶
抑制剂,用于治疗(包括预防性治疗)糖尿病的长期并发症,以及制备治疗(包括预防性治疗)糖尿病的药物。上述材料的药物组合物。6- 不饱和 n-6
脂肪酸(G
LA 或 DG
LA 除外)的
抗坏血酸酯本身。